← All stocks

Exelixis, Inc.

EXELBiotechnologyLatest filing used: 2026-10-29Filings on SEC EDGAR ↗

Above fair value Strong balance sheet Fast grower High cash margin Uncertain estimate

Fair value per share

$36.55

from SEC filings only

Last close

$68.99

Nov 13, 2026

88.8% above fair value

Margin of safety price
$27.41
25% below fair value
Stress case
$16.24
if things go badly

Its filings point to about $36.55 a share, most likely between $22.30 and $65.04.

Where it sits

332 of the 653 stocks we value that have a close are even further above their estimates.

Counts the 653 stocks that have both a value and a close as of Nov 13. Positions are squeezed so the biggest gaps fit.

The short case

In favour

  • It turns about 29% of its sales into cash in a typical year.
  • Sales have grown about 19% a year over the last five years.
  • It holds more cash than debt.

Against

  • Its last close is about 89% above what its filings say it is worth.
  • The estimate is uncertain: the likely range runs from $22.30 to $65.04.
  • In a bad stretch the filings support only about $16.24 a share.

Written automatically from the filings, by the same rules for every company. Not a recommendation.

Price tags

The last close next to our fair value, the filings-based estimate above. Profit and cash flow: the 12 months to October 2, 2026.

MeasureAt last close$68.99Nov 13At our fair value$36.55
Market valueAll 256 million shares at that price (the diluted count, which includes stock options and awards)$17.6B$9.3B
Price / earnings (P/E)Dollars paid for each $1 of yearly profit19.9×10.6×
Price / free cash flowDollars paid for each $1 of cash left each year after paying for equipment15.2×8.1×
EV / EBITDAPrice of the whole business (shares plus debt, less cash) for each $1 of yearly profit before interest, tax and wear and tearNot shown: we couldn't find every number this needs in the filings.Not shown: we couldn't find every number this needs in the filings.

Our own arithmetic on the filings, the last close and our fair value, which is an estimate. One unusual year can push any of these very high or very low. How we work these out

Five areas

19 of 25 checks passedStrong in 4 of 5 areas

GrowthStrong · 5 of 5
  • Revenue up 5%+ a year over 3 years (passed)
  • Revenue up 5%+ a year over 5 years (passed)
  • Earnings per share up 5%+ a year over 5 years (passed)
  • Revenue up over the last 12 months (passed)
  • Earnings per share up over the last 12 months (passed)
ProfitabilityStrong · 4 of 5
  • Return on equity of 15%+ (last 12 months) (passed)
  • Return on equity of 12%+ (5-year average) (passed)
  • Return on invested capital of 10%+ (5-year average) (no data)
  • Operating margin of 10%+ (5-year average) (passed)
  • Operating margin holding up (last 12 months vs 5 years) (passed)
Cash generationStrong · 5 of 5
  • Cash earnings positive in almost every year (at most one bad year) (passed)
  • Typical year turns 10%+ of revenue into cash (passed)
  • Latest year at or above the typical year (passed)
  • Free cash flow positive (last 12 months) (passed)
  • Revenue larger than 5 years ago (passed)
Balance sheetStrong · 4 of 5
  • Debt no larger than equity (no data)
  • Cash and short-term investments exceed debt (passed)
  • Positive shareholders' equity (passed)
  • Debt clearly tagged in the filings (passed)
  • Operating margin above zero (last 12 months) (passed)
Shareholder returnsWeak · 1 of 5
  • Pays a dividend (not passed)
  • Dividend paid in each of the last 5 years (not passed)
  • Dividend grew over 5 years (no data)
  • Pays out 75% or less of earnings (no data)
  • Share count flat or falling over 5 years (passed)

Flags

No flags raised in the latest filing.

How we got this number

In a typical year EXEL kept 24% of its revenue as cash after running and maintaining the business (before interest). We assume revenue grows 7.0% a year for five years, then slows to 2.5% by year ten, and discount the cash at 10.2% a year (the 10-year Treasury yield plus 5 points). That is worth $36.55 a share today.

Technical details
Model
Discounted cash flow on cash earnings
Cash-earnings margin: typical year (worst / best 3-year stretch)
23.6% (14.2% / 42.4%)
Years used
2018–2026
Revenue growth, years 1–5 (range tested)
7.0% (2 to 12%)
Capital needed per $1 of new revenue
$0.06 equipment, $0.12 working capital
Discount rate
10.2%
Revenue base
$2.3B (lower of TTM and last FY)
Debt / cash
$0.0B / $0.9B
Value if investors require Treasury + 3 / + 8 points (we use + 5)
$45.77 / $28.13
If growth after year 10 keeps today's returns
$41.06
Likely range
10th–90th percentile of 4,000 runs with different assumptions
Required return
10-year Treasury 5.15% (2026-11-13) + 5%

What the price assumes

For our model to reach the last close of $68.99 (Nov 13, 2026), EXEL would have to keep 46¢ of every $1 of sales as cash. In a typical year it kept 24¢.

What the price needs
46¢
Its typical year
24¢
Its last 3 years
25¢
Its best year
52¢
Its worst year
10¢

In our model, the last close needs a better-than-typical year, within its own record.

Typical, best and worst years are from the 8 years we checked in its filings (2018–2026). Everything else stays as described above, including the growth path and the discount rate.

Technical details

Value per share is a straight line in the margin until it reaches zero: value = margin × cash factor − (growth spending + debt and other claims) per share. We solve for the margin that gives the last close, with growth, discount rate, equipment and working capital held as in the main model.

Revenue base $2.3B. Growth 7.0% for five years, fading to 2.5% by year 10. Discount rate 10.2%. At 23.6¢ the filings-based value is $36.55. Each extra 1¢ of margin adds $1.43 a share. The last close is $68.99, which is $32.44 above the filings-based value, so the margin would have to rise by 22.8¢, to 46.4¢.

Terminal rule: Growth after year 10 earns only the discount rate, so it adds no value.

Ten years of results

Revenue

$2.3B in FY2026, up 7% on the year before

FY2016: $191MFY2017: $452MFY2018: $854MFY2020: $968MFY2021: $988MFY2021: $1.4BFY2022: $1.6BFY2023: $1.8BFY2025: $2.2BFY2026: $2.3B$1.2B$2.5BFY16FY20FY22FY26$2.3B
Show as table
YearRevenue
FY2016$191M
FY2017$452M
FY2018$854M
FY2020$968M
FY2021$988M
FY2021$1.4B
FY2022$1.6B
FY2023$1.8B
FY2025$2.2B
FY2026$2.3B

Cash earnings as a share of sales

35.4% of sales in FY2026

FY2018: 51.7%FY2020: 40.2%FY2021: 18.6%FY2021: 18.6%FY2022: 13.7%FY2023: 10.3%FY2025: 28.7%FY2026: 35.4%0%30%60%FY16FY20FY22FY2635%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY201851.7%
FY202040.2%
FY202118.6%
FY202118.6%
FY202213.7%
FY202310.3%
FY202528.7%
FY202635.4%

Shares outstanding

Share count fell 10% over 9 years

FY2017: 312MFY2018: 313MFY2020: 315MFY2021: 318MFY2021: 322MFY2022: 325MFY2023: 321MFY2025: 296MFY2026: 282M0200M400MFY16FY20FY22FY26281.9M
Show as table
YearShares outstanding
FY2016–
FY2017312M
FY2018313M
FY2020315M
FY2021318M
FY2021322M
FY2022325M
FY2023321M
FY2025296M
FY2026282M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-10-29. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13. Price tags: our own arithmetic on the SEC figures, the last close and our fair value.